<DOC>
	<DOCNO>NCT02651688</DOCNO>
	<brief_summary>The purpose study compare effect 12 month treatment enclomiphene 12.5 mg , 25 mg , placebo capsule body composition metabolic parameter overweight men acquire hypogonadotropic hypogonadism ( confirmed morning T≤300 ng/dL ) follow 6 month diet 15 month exercise program .</brief_summary>
	<brief_title>A Multi-Center Study Men With Acquired Hypogonadotropic Hypogonadism Compare Changes Body Composition Metabolic Parameters With Diet Exercise Conjunction With Treatment With 12.5 mg 25 mg Enclomiphene</brief_title>
	<detailed_description>To compare effect 12 month treatment enclomiphene 12.5 mg , 25 mg , placebo capsule body composition metabolic parameter overweight men acquire hypogonadotropic hypogonadism ( confirmed morning T≤300 ng/dL ) follow 6 month diet 15 month exercise program . Subjects must treat testosterone product 6 month prior study must ever use testosterone product year longer .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Overweight ( BMI 30 42 kg/m2 inclusive ) male age 18 60 inclusive 2 . Waist circumference ≥ 40 inch ( 101.6 cm ) 3 . Previously concurrently diagnose secondary hypogonadism . 4 . Must 2 morning testosterone assessment Visit 1 , collect 10 AM , 24 day apart , must ≤ 300ng/dL . 5 . LH &gt; 1.4 &lt; 9.4 mIU/mL ( Visit 1 ) 6 . HbA1c ≤7.5 7 . Stable weight last 3 month ( +/ 10 pound ) 8 . Lives work within 10 mile gym use study 9 . Must fit enough participate fitness program 10 . Ability complete study compliance protocol requirement 11 . Ability understand provide write informed consent 1 . Any use testosterone product ( injectable , pelleted , transdermal sublingual ) 6 month prior study prior use testosterone product 12 month long time . 2 . Use testosterone , Clomid , 5αreductase inhibitor , hCG , androgen , estrogen , anabolic steroid , DHEA , herbal hormone product study 3 . Use Clomid past year 4 . Known hypersensitivity Clomid 5 . Allergy soy , peanuts latex 6 . Chronic use glucocorticoid ( chronic use inhale topical glucocorticoid acceptable ) 7 . History drug abuse chronic narcotic use include methadone 8 . A recent history alcoholism illegal substance steroid abuse ( &lt; 2 year ) presence moderate alcohol use ( &gt; 21 drink per week ) 9 . Use investigational drug product , participation drug medical device research study within 30 day prior receive study medication 10 . A hematocrit &gt; 54 % 11 . Presence know history hyperprolactinemia without tumor ( prolactin &gt; 20 ng/mL ) 12 . Current history prostate cancer suspicion prostate disease unless rule prostate biopsy , PSA &gt; 3.6 13 . Current history breast cancer 14 . Uncontrolled hypertension base Investigator 's assessment screen 15 . History bulimia nervosa binge eat 16 . Subject ( ) lap band undergone gastric bypass surgery 17 . Subject celiac disease gluten intolerance 18 . Subject Type I diabetes 19 . Subject condition opinion investigator would interfere participant 's ability provide inform consent , comply study instruction , possibly confound interpretation study result , endanger participant take part study 20 . Enrolled randomized ( applicable ) previous enclomiphene study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>